J Rhinol.  2015 Nov;22(2):75-81. 10.18787/jr.2015.22.2.75.

Differences of Short-Term Systemic Responses in Obstructive Sleep Apnea Patient by Compliance of Continuous Positive Airway Pressure

• Jeong JI
• Kim SJ
• Hong SD
• Chung SK
• Dhong HJ
• Kim HY

• KMID: 2223201
• DOI: http://doi.org/10.18787/jr.2015.22.2.75

Abstract

BACKGROUND
Obstructive sleep apnea (OSA) is characterized by repeated apnea, hypopnea, and micro-arousals during sleep. Many studies have described correlations between OSA and multiple systemic diseases, such as cardiovascular, cerebrovascular, and metabolic diseases. The aim of this study was to determine whether the compliance of continuous positive airway pressure (CPAP) affects the short-term systemic responses in OSA patients.
METHODS
Twenty-four newly diagnosed OSA patients were enrolled. All subjects used CPAP for 4 weeks. The subjects were divided into two groups according to the rate of using CPAP over 4 hours per night. Complete blood cell count, coagulation results, blood chemistry, lipid profiles, and pulmonary function results were evaluated at baseline, and were followed up after 4 weeks.
RESULTS
After CPAP treatment, WBC count, hemoglobin, hematocrit, albumin, AST, ALT, Cl, and peak expiratory flow rate (PEFR) were significantly changed in the higher compliance group (n=14), whereas platelet count and triglyceride levels were significantly changed in the lower compliance group (n=10). In multivariate analysis, the changes in WBC count, hemoglobin and hematocrit were statistically significant between the higher compliance and lower compliance groups (p=0.0056, 0.0016, and 0.0051).
CONCLUSION
The compliance of CPAP affects the short-term systemic responses in OSA patient.

Keyword

OSA; CPAP; Intermittent hypoxia; Oxidative stress; Compliance of CPAP

MeSH Terms

Apnea
Blood Cell Count
Chemistry
Compliance*
Continuous Positive Airway Pressure*
Hematocrit
Humans
Metabolic Diseases
Multivariate Analysis
Oxidative Stress
Peak Expiratory Flow Rate
Platelet Count
Sleep Apnea, Obstructive*
Triglycerides

Reference

References

1). Chung YS. Pathogenesis of Obstructive Sleep Apnea. J Rhinol. 2009; 16:87–90.

2). Kim J, In K, Kim J, You S, Kang K, Shim J, et al. Prevalence of sleep-disordered breathing in middle-aged Korean men and women. Am J Respir Crit Care Med. 2004; 170:1108–13.

3). Mo JH. Obstructive Sleep Apnea and Systemic Diseases. J Rhinol. 2013; 20:8–12.

4). Jullian-Desayes I, Joyeux-Faure M, Tamisier R, Launois S, Borel AL, Levy P, et al. Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: a systematic review from sham CPAP randomized controlled trials. Sleep Med Rev. 2015; 21:23–38.

5). Unnikrishnan D, Jun J, Polotsky V. Inflammation in sleep apnea: an update. Rev Endocr Metab Disord. 2015; 16:25–34.

6). Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration. 2009; 78:141–6.

7). Guilleminault C, Abad VC. Obstructive sleep apnea syndromes. Med Clin North Am. 2004; 88:611–30. viii.

8). Weaver TE, Maislin G, Dinges DF, Bloxham T, George CF, Greenberg H, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007; 30:711–9.

9). Steiropoulos P, Kotsianidis I, Nena E, Tsara V, Gounari E, Hatzizi-si O, et al. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep. 2009; 32:537–43.

10). Chin K, Nakamura T, Takahashi K, Sumi K, Ogawa Y, Masuzaki H, et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med. 2003; 114:370–6.

11). Norman D, Bardwell WA, Arosemena F, Nelesen R, Mills PJ, Lore-do JS, et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep. 2008; 31:121–6.

12). Lin MT, Lin HH, Lee PL, Weng PH, Lee CC, Lai TC, et al. Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: a metaanalysis. Sleep Breath. 2015; 19:809–17.

13). Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. Chest. 2015; 147:266–74.

14). Karamanlı H1. Özol D, Ugur KS, Yıldırım Z, Armutçu F, Bozkurt B, et al. Influence of CPAP treatment on airway and systemic inflammation in OSAS patients. Sleep Breath. 2014; 18:251–6.

15). Sökücü SN, Ozdemir C, Dalar L, Karasulu L, Aydın S, Altın S. Complete blood count alterations after six months of continuous positive airway pressure treatment in patients with severe obstructive sleep apnea. J Clin Sleep Med. 2014; 10:873–8.

16). Umlauf MG, Chasens ER. Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med Rev. 2003; 7:403–11.

17). Varol E, Ozturk O, Yucel H, Gonca T, Has M, Dogan A, et al. The effects of continuous positive airway pressure therapy on mean platelet volume in patients with obstructive sleep apnea. Platelets. 2011; 22:552–6.

18). Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax. 2004; 59:777–82.

19). Phillips CL, Yee BJ, Marshall NS, Liu PY, Sullivan DR, Grunstein RR. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial. Am J Respir Crit Care Med. 2011; 184:355–61.

20). Schlatzer C, Schwarz EI, Kohler M. The effect of continuous positive airway pressure on metabolic variables in patients with obstructive sleep apnoea. Chron Respir Dis. 2014; 11:41–52.